Muscle Mass is a Key Metric in Cancer Care and GLP-1 Therapy

As GLP-1 receptor agonists like Ozempic and Wegovy continue to dominate headlines for their transformative weight loss results, a critical conversation is emerging within the oncology community.

For patients with cancer and survivors, the numbers on the scale only tell part of the story. Experts at Virginia Cancer Specialists are now sounding the alarm: while losing fat is beneficial, preserving muscle mass is a matter of durability and survival.

In a recent interview, Kristin Lupton, PA-C, and Dr. David Weintritt shared insights into how they are navigating the intersection of weight management medications and oncological health.

The 20% risk: Not all weight loss is equal

The rise of GLP-1 therapies has provided a powerful tool for reducing obesity, a known risk factor for various malignancies. However, Lupton warns that this progress comes with a caveat. "Up to 20% of that weight loss can be muscle mass," Lupton noted.

For a patient undergoing or recovering from cancer treatment, that 20% can be the difference between resilience and frailty. Lupton, a proponent of these medications when managed correctly, emphasizes the need for advanced body composition monitoring.

By using modern tools, she can track the specific ratio of fat mass to muscle mass from the moment a patient begins therapy. "We can refer them out to nutrition if their muscle mass is decreasing too rapidly," she explained, noting that most of her successful patients lose significant fat while only dropping a "couple pounds" of lean muscle.

Durability and the sarcopenia threat

Weintritt highlighted the broader implications of muscle loss, particularly for patients facing the rigors of surgery and chemotherapy. While losing visceral fat immediately lowers cancer risks, especially in the female population, ignoring muscle health leads to a dangerous condition known as sarcopenia.

“Weights [are] one metric... but if you don't address the potential for this term sarcopenia, then you can have situations where individuals may not be as durable when it comes to complying with regimens of care," Weintritt said.

In the oncology world, "durability" is a vital asset. Patients with low muscle mass often find it significantly more difficult to navigate the months-long journey between surgery, chemotherapy and other systemic treatments. A frail state can lead to treatment interruptions or an inability to tolerate necessary dosages, directly impacting outcomes.

A counterbalance for recurrence

The benefits of maintaining muscle density extend far beyond the initial treatment phase. Weintritt pointed out that being active enough to maintain or increase muscle density acts as a critical "counterbalance" to obesity. This trend is increasingly recognized as a key factor in reducing both cancer occurrence and recurrence.

"We still don't know necessarily, in somebody who's in a poor state of health, exactly what is it that happened? We just know that things happen more often in people in that situation," Weintritt observed.

The takeaway for patients is clear: Weight loss is a marathon, not a sprint, and the goal is to emerge stronger, not just smaller. By combining GLP-1 therapy with rigorous body composition tracking and nutritional support, providers are ensuring that their patients are not just losing weight, but gaining the durability they need to beat cancer.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.